Arm 1 will receive an intensive regimen of anti-helminthic therapy consisting of albendazole every three months for two years and praziquantel at enrollment and at one year of follow up.

Arm 2 will receive symptomatic diagnosis and treatment of helminth infection as is current standard of care in Kenya.

HIV Infections

Helminthiasis

Every 3 months for 24 months (enrollment 3, 6, 9, 12, 15, 18, 21, and 24 months):
400mg/day X 3 days

Albendazole

Praziquantel

Current standard of care for HIV patients in Kenya based on WHO guidelines.

Current standard of care in Kenya

Kenya Medical Research Institute

Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression

The primary measure of efficacy for the randomized clinical trial is the time to ART eligibility and the time to CD4 counts of less than 200 and 350 cells/mm3.

Secondary measures of efficacy will include changes in WHO Clinical Staging, development of IRIS, time to hospitalization, time to death, time to initiation of ARVs and CD4 response to ARVs as well as the development of IRIS among those who initiate ARVs.

isoquinoline/dolor abdominal

Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression

La base de dades d’herbes medicinals més completa avalada per la ciència